Neonatal Toxicology Market Size, Share & Trends Analysis Report By Specimen (Urine, Umbilical Cord), By Drug (Cannabinoids, Opioids), By Technology, By End Use, By Region, And Segment Forecasts, 2024 - 2030
This report can be delivered to the clients within 2 Business Days
Neonatal Toxicology Market Growth & Trends
The global neonatal toxicology market size is expected t%li%reach USD 514.05 million by 2030, at a projected CAGR of 10.6% from 2024 t%li%2030, according t%li%a new report by Grand View Research, Inc. The rising prevalence of neonatal disorders, such as neonatal abstinence syndrome (NAS) due t%li%maternal drug use, drives the demand for neonatal toxicology testing and treatments. In addition, the development of advanced diagnostic technologies, such as mass spectrometers, improves the detection and management of toxic exposures in neonates, thereby propelling market growth.
This alarming trend underscores the urgent need for effective neonatal toxicology solutions. Over the past several decades, there have been significant advancements in drug screening tools, which now provide more accurate and precise results than ever before. Traditionally, drug testing has been performed using enzyme-linked immunosorbent assays (ELISAs). This method has several advantages: it is relatively inexpensive, easy t%li%perform in a general laboratory, and has a rapid turnaround time. Moreover, the long-standing use of ELISA has resulted in the availability of multiple commercial antibodies validated for use in various human tissues. For certain tests, such as detecting cocaine metabolites in urine, ELISA is a reliable method. However, for other drug and tissue combinations, there is a relatively high incidence of both false positives and negatives.
In addition, Mass General Brigham, Massachusetts' largest healthcare system, in April 2024 announced a significant shift in its approach t%li%reporting suspected abuse or neglect in cases where a baby is born exposed t%li%drugs. This policy change, now adopted by systems like Yale New Haven Children’s Hospital and Boston Medical Center, signifies a broader trend toward more compassionate and evidence-based responses t%li%substance use during pregnancy. Rather than reporting every instance of drug exposure at birth, these health systems will only report if there is reasonable cause t%li%believe the infant is at risk of physical or emotional injury. This approach reflects a growing consensus that punitive measures lead t%li%worse medical outcomes for both parent and child and disproportionately impact families of color and those with low socioeconomic status. This evolving policy landscape has profound implications for the neonatal toxicology testing industry. The shift away from punitive approaches towards more supportive and rehabilitative measures is expected t%li%drive changes in the demand and utilization of neonatal toxicology tests.
With revised state laws in places like Connecticut, New Mexico, Washington, and Colorad%li%and pending legislation in Massachusetts t%li%protect mothers on prescribed medications for substance use disorder, the criteria for conducting toxicology tests may become more refined. This could lead t%li%more targeted testing, ensuring that resources are used efficiently and that testing is conducted only when truly necessary. In addition, as the market shifts towards supportive care, there is significant potential for growth in emerging technologies that offer comprehensive and minimally invasive screening solutions. This includes advancements in technologies like high-resolution mass spectrometry and innovative biomarkers that can provide more detailed insights int%li%neonatal exposure and health without extensive invasive procedures.
Neonatal Toxicology Market Report Highlights
Neonatal Toxicology Market Growth & Trends
The global neonatal toxicology market size is expected t%li%reach USD 514.05 million by 2030, at a projected CAGR of 10.6% from 2024 t%li%2030, according t%li%a new report by Grand View Research, Inc. The rising prevalence of neonatal disorders, such as neonatal abstinence syndrome (NAS) due t%li%maternal drug use, drives the demand for neonatal toxicology testing and treatments. In addition, the development of advanced diagnostic technologies, such as mass spectrometers, improves the detection and management of toxic exposures in neonates, thereby propelling market growth.
This alarming trend underscores the urgent need for effective neonatal toxicology solutions. Over the past several decades, there have been significant advancements in drug screening tools, which now provide more accurate and precise results than ever before. Traditionally, drug testing has been performed using enzyme-linked immunosorbent assays (ELISAs). This method has several advantages: it is relatively inexpensive, easy t%li%perform in a general laboratory, and has a rapid turnaround time. Moreover, the long-standing use of ELISA has resulted in the availability of multiple commercial antibodies validated for use in various human tissues. For certain tests, such as detecting cocaine metabolites in urine, ELISA is a reliable method. However, for other drug and tissue combinations, there is a relatively high incidence of both false positives and negatives.
In addition, Mass General Brigham, Massachusetts' largest healthcare system, in April 2024 announced a significant shift in its approach t%li%reporting suspected abuse or neglect in cases where a baby is born exposed t%li%drugs. This policy change, now adopted by systems like Yale New Haven Children’s Hospital and Boston Medical Center, signifies a broader trend toward more compassionate and evidence-based responses t%li%substance use during pregnancy. Rather than reporting every instance of drug exposure at birth, these health systems will only report if there is reasonable cause t%li%believe the infant is at risk of physical or emotional injury. This approach reflects a growing consensus that punitive measures lead t%li%worse medical outcomes for both parent and child and disproportionately impact families of color and those with low socioeconomic status. This evolving policy landscape has profound implications for the neonatal toxicology testing industry. The shift away from punitive approaches towards more supportive and rehabilitative measures is expected t%li%drive changes in the demand and utilization of neonatal toxicology tests.
With revised state laws in places like Connecticut, New Mexico, Washington, and Colorad%li%and pending legislation in Massachusetts t%li%protect mothers on prescribed medications for substance use disorder, the criteria for conducting toxicology tests may become more refined. This could lead t%li%more targeted testing, ensuring that resources are used efficiently and that testing is conducted only when truly necessary. In addition, as the market shifts towards supportive care, there is significant potential for growth in emerging technologies that offer comprehensive and minimally invasive screening solutions. This includes advancements in technologies like high-resolution mass spectrometry and innovative biomarkers that can provide more detailed insights int%li%neonatal exposure and health without extensive invasive procedures.
Neonatal Toxicology Market Report Highlights
- Based on the specimen, meconium accounted for the largest revenue share in 2023. Meconium specimens offer a key advantage in neonatal toxicology by detecting drug exposure over the last trimester of pregnancy, providing a longer detection window.
- Based on technology, mass spectroscopy dominated the market in 2023.Mass spectrometry is the gold standard in neonatal toxicology, offering unparalleled sensitivity and specificity for detecting drug exposure at nanogram levels. Its advantages include high accuracy, low detection limits, and the ability t%li%confirm positive results from initial screenings.
- Based on the drug, the cannabinoids segment dominated the market in 2023 with the largest market share. Cannabinoid use during pregnancy is rising, with 2-5% of pregnant women self-reporting use and rates as high as 28% among low-income urban women. This increase is driven by legalization, perceived safety, and use for nausea.
- Based on end use, the clinical laboratories segment dominated the market with the largest revenue share in 2023. Arup Laboratories and Quest Diagnostics are key players in the market, providing comprehensive testing services t%li%detect prenatal drug exposure.
- North America dominated the market due t%li%the presence of a large number of major market players, the high prevalence of neonatal drug exposure, and the increasing awareness of the adverse effects of prenatal drug abuse.
- The Asia Pacific region is expected t%li%witness the fastest CAGR over the forecast period from 2024 t%li%2030. Due t%li%the expansion of healthcare infrastructure and the implementation of public health initiatives aimed at reducing drug abuse during pregnancy, market growth is expected in this region.
CHAPTER 1. METHODOLOGY AND SCOPE
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Specimen
1.2.2. Technology
1.2.3. Drug
1.2.4. End User
1.2.5. Regional scope
1.2.6. Estimates and forecasts timeline.
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Specimen outlook
2.2.2. Technology outlook
2.2.3. Drug outlook
2.2.4. End User outlook
2.2.5. Regional outlook
2.3. Competitive Insights
CHAPTER 3. NEONATAL TOXICOLOGY MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook.
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. High prevalence of substance abuse
3.2.1.2. Stringent laws mandating alcohol and drug testing
3.2.1.3. Increasing government initiatives to monitor substance abuse
3.2.2. Market restraint analysis
3.2.2.1. Neonatal toxicology is considered a violation of privacy rights in some countries
3.3. Neonatal Toxicology Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.2. PESTEL Analysis
CHAPTER 4. NEONATAL TOXICOLOGY MARKET: SPECIMEN ESTIMATES & TREND ANALYSIS
4.1. Specimen Market Share, 2023 & 2030
4.2. Segment Dashboard
4.3. Global Neonatal Toxicology Market by Specimen Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.4.1. Urine
4.4.1.1. Urine market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2. Umbilical Cord
4.4.2.1. Umbilical cord market estimates and forecasts 2018 to 2030 (USD Million)
4.4.3. Meconium
4.4.3.1. Meconium market estimates and forecasts 2018 to 2030 (USD Million)
4.4.4. Others
4.4.4.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 5. NEONATAL TOXICOLOGY MARKET: TECHNOLOGY ESTIMATES & TREND ANALYSIS
5.1. Technology Market Share, 2023 & 2030
5.2. Segment Dashboard
5.3. Global Neonatal Toxicology Market by Technology Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.4.1. Mass spectroscopy
5.4.1.1. Mass spectroscopy market estimates and forecasts 2018 to 2030 (USD Million)
5.4.2. Immunoassay
5.4.2.1. Immunoassay market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 6. NEONATAL TOXICOLOGY MARKET: DRUG TYPE ESTIMATES & TREND ANALYSIS
6.1. Drug type Market Share, 2023 & 2030
6.2. Segment Dashboard
6.3. Global Neonatal Toxicology Market by Drug type Outlook
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
6.4.1. Cannabinoids
6.4.1.1. Cannabinoids Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.2. Opioids
6.4.2.1. Opioids Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.3. Cocaine
6.4.3.1. Cocaine Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.4. Benzodiazepines
6.4.4.1. Benzodiazepines market estimates and forecasts 2018 to 2030 (USD Million)
6.4.5. Amphetamines
6.4.5.1. Amphetamines Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.6. Other illicit drugs
6.4.6.1. Other illicit drugs Market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 7. NEONATAL TOXICOLOGY MARKET: END USER ESTIMATES & TREND ANALYSIS
7.1. End User Market Share, 2023 & 2030
7.2. Segment Dashboard
7.3. Global Neonatal Toxicology Market by End User Outlook
7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
7.4.1. Hospitals
7.4.1.1. Hospitals Market estimates and forecasts 2018 to 2030 (USD Million)
7.4.2. Clinical Laboratories
7.4.2.1. Clinical Laboratories Market estimates and forecasts 2018 to 2030 (USD Million)
7.4.3. Others
7.4.3.1. Others Market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 8. NEONATAL TOXICOLOGY MARKET: REGIONAL ESTIMATES & TREND ANALYSIS
8.1. Regional Market Share Analysis, 2023 & 2030
8.2. Regional Market Dashboard
8.3. Global Regional Market Snapshot
8.4. Market Size & Forecasts Trend Analysis, 2018 to 2030:
8.5. North America
8.5.1. North America
8.5.2. U.S.
8.5.2.1. Key country dynamics
8.5.2.2. Regulatory framework
8.5.2.3. Competitive scenario
8.5.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
8.5.3. Canada
8.5.3.1. Key country dynamics
8.5.3.2. Regulatory framework
8.5.3.3. Competitive scenario
8.5.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
8.5.4. Mexico
8.5.4.1. Key country dynamics
8.5.4.2. Regulatory framework
8.5.4.3. Competitive scenario
8.5.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
8.6. Europe
8.6.1. Europe
8.6.2. UK
8.6.2.1. Key country dynamics
8.6.2.2. Regulatory framework/ Reimbursement
8.6.2.3. Competitive scenario
8.6.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
8.6.3. Germany
8.6.3.1. Key country dynamics
8.6.3.2. Regulatory framework/ Reimbursement
8.6.3.3. Competitive scenario
8.6.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
8.6.4. France
8.6.4.1. Key country dynamics
8.6.4.2. Regulatory framework/ Reimbursement
8.6.4.3. Competitive scenario
8.6.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
8.6.5. Italy
8.6.5.1. Key country dynamics
8.6.5.2. Regulatory framework/ Reimbursement
8.6.5.3. Competitive scenario
8.6.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
8.6.6. Spain
8.6.6.1. Key country dynamics
8.6.6.2. Regulatory framework
8.6.6.3. Competitive scenario
8.6.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
8.6.7. Norway
8.6.7.1. Key country dynamics
8.6.7.2. Regulatory framework
8.6.7.3. Competitive scenario
8.6.7.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
8.6.8. Sweden
8.6.8.1. Key country dynamics
8.6.8.2. Regulatory framework
8.6.8.3. Competitive scenario
8.6.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
8.6.9. Denmark
8.6.9.1. Key country dynamics
8.6.9.2. Regulatory framework/ Reimbursement
8.6.9.3. Competitive scenario
8.6.9.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
8.7. Asia Pacific
8.7.1. Asia Pacific
8.7.2. Japan
8.7.2.1. Key country dynamics
8.7.2.2. Regulatory framework/ Reimbursement
8.7.2.3. Competitive scenario
8.7.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
8.7.3. China
8.7.3.1. Key country dynamics
8.7.3.2. Regulatory framework/ Reimbursement
8.7.3.3. Competitive scenario
8.7.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
8.7.4. India
8.7.4.1. Key country dynamics
8.7.4.2. Regulatory framework/ Reimbursement
8.7.4.3. Competitive scenario
8.7.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
8.7.5. Australia
8.7.5.1. Key country dynamics
8.7.5.2. Regulatory framework/ Reimbursement
8.7.5.3. Competitive scenario
8.7.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
8.7.6. South Korea
8.7.6.1. Key country dynamics
8.7.6.2. Regulatory framework/ Reimbursement
8.7.6.3. Competitive scenario
8.7.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
8.7.7. Thailand
8.7.7.1. Key country dynamics
8.7.7.2. Regulatory framework/ Reimbursement
8.7.7.3. Competitive scenario
8.7.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
8.8. Latin America
8.8.1. Latin America
8.8.2. Brazil
8.8.2.1. Key country dynamics
8.8.2.2. Regulatory framework
8.8.2.3. Competitive scenario
8.8.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
8.8.3. Argentina
8.8.3.1. Key country dynamics
8.8.3.2. Regulatory framework/ Reimbursement
8.8.3.3. Competitive scenario
8.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
8.9. MEA
8.9.1. MEA
8.9.2. South Africa
8.9.2.1. Key country dynamics
8.9.2.2. Regulatory framework/ Reimbursement
8.9.2.3. Competitive scenario
8.9.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
8.9.3. Saudi Arabia
8.9.3.1. Key country dynamics
8.9.3.2. Regulatory framework/ Reimbursement
8.9.3.3. Competitive scenario
8.9.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
8.9.4. UAE
8.9.4.1. Key country dynamics
8.9.4.2. Regulatory framework/ Reimbursement
8.9.4.3. Competitive scenario
8.9.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
8.9.5. Kuwait
8.9.5.1. Key country dynamics
8.9.5.2. Regulatory framework
8.9.5.3. Competitive scenario
8.9.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 9. COMPETITIVE LANDSCAPE
9.1. Recent Developments & Impact Analysis, By Key Market Participants
9.2. Company/Competition Categorization
9.3. Vendor Landscape
9.3.1. List of key distributors and channel partners
9.3.2. Key customers
9.3.3. Key company market share analysis, 2023
9.3.4. Quest Diagnostics Incorporated
9.3.4.1. Company overview
9.3.4.2. Financial performance
9.3.4.3. Others benchmarking
9.3.4.4. Strategic initiatives
9.3.5. USDTL
9.3.5.1. Company overview
9.3.5.2. Financial performance
9.3.5.3. Others benchmarking
9.3.5.4. Strategic initiatives
9.3.6. Quidel Corporation
9.3.6.1. Company overview
9.3.6.2. Financial performance
9.3.6.3. Others benchmarking
9.3.6.4. Strategic initiatives
9.3.7. Thermo Fisher Scientific, Inc.
9.3.7.1. Company overview
9.3.7.2. Financial performance
9.3.7.3. Others benchmarking
9.3.7.4. Strategic initiatives
9.3.8. Omega Laboratories, Inc.
9.3.8.1. Company overview
9.3.8.2. Financial performance
9.3.8.3. Others benchmarking
9.3.8.4. Strategic initiatives
9.3.9. Bio-Rad Laboratories, Inc.
9.3.9.1. Company overview
9.3.9.2. Financial performance
9.3.9.3. Others benchmarking
9.3.9.4. Strategic initiatives
9.3.10. Agilent Technologies, Inc.
9.3.10.1. Company overview
9.3.10.2. Financial performance
9.3.10.3. Others benchmarking
9.3.10.4. Strategic initiatives
9.3.11. Laboratory Corporation of America Holdings
9.3.11.1. Company overview
9.3.11.2. Financial performance
9.3.11.3. Others benchmarking
9.3.11.4. Strategic initiatives
9.3.12. Clinical Reference Laboratory, Inc.
9.3.12.1. Company overview
9.3.12.2. Financial performance
9.3.12.3. Others benchmarking
9.3.12.4. Strategic initiatives
9.3.13. Cordant Health Solutions
9.3.13.1. Company overview
9.3.13.2. Financial performance
9.3.13.3. Others benchmarking
9.3.13.4. Strategic initiatives
1.1. Market Segmentation & Scope
1.2. Segment Definitions
1.2.1. Specimen
1.2.2. Technology
1.2.3. Drug
1.2.4. End User
1.2.5. Regional scope
1.2.6. Estimates and forecasts timeline.
1.3. Research Methodology
1.4. Information Procurement
1.4.1. Purchased database
1.4.2. GVR’s internal database
1.4.3. Secondary sources
1.4.4. Primary research
1.4.5. Details of primary research
1.5. Information or Data Analysis
1.5.1. Data analysis models
1.6. Market Formulation & Validation
1.7. Model Details
1.7.1. Commodity flow analysis (Model 1)
1.7.2. Approach 1: Commodity flow approach
1.7.3. Volume price analysis (Model 2)
1.7.4. Approach 2: Volume price analysis
1.8. List of Secondary Sources
1.9. List of Primary Sources
1.10. Objectives
CHAPTER 2. EXECUTIVE SUMMARY
2.1. Market Outlook
2.2. Segment Outlook
2.2.1. Specimen outlook
2.2.2. Technology outlook
2.2.3. Drug outlook
2.2.4. End User outlook
2.2.5. Regional outlook
2.3. Competitive Insights
CHAPTER 3. NEONATAL TOXICOLOGY MARKET VARIABLES, TRENDS & SCOPE
3.1. Market Lineage Outlook
3.1.1. Parent market outlook
3.1.2. Related/ancillary market outlook.
3.2. Market Dynamics
3.2.1. Market driver analysis
3.2.1.1. High prevalence of substance abuse
3.2.1.2. Stringent laws mandating alcohol and drug testing
3.2.1.3. Increasing government initiatives to monitor substance abuse
3.2.2. Market restraint analysis
3.2.2.1. Neonatal toxicology is considered a violation of privacy rights in some countries
3.3. Neonatal Toxicology Market Analysis Tools
3.3.1. Industry Analysis - Porter’s
3.3.2. PESTEL Analysis
CHAPTER 4. NEONATAL TOXICOLOGY MARKET: SPECIMEN ESTIMATES & TREND ANALYSIS
4.1. Specimen Market Share, 2023 & 2030
4.2. Segment Dashboard
4.3. Global Neonatal Toxicology Market by Specimen Outlook
4.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
4.4.1. Urine
4.4.1.1. Urine market estimates and forecasts 2018 to 2030 (USD Million)
4.4.2. Umbilical Cord
4.4.2.1. Umbilical cord market estimates and forecasts 2018 to 2030 (USD Million)
4.4.3. Meconium
4.4.3.1. Meconium market estimates and forecasts 2018 to 2030 (USD Million)
4.4.4. Others
4.4.4.1. Others market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 5. NEONATAL TOXICOLOGY MARKET: TECHNOLOGY ESTIMATES & TREND ANALYSIS
5.1. Technology Market Share, 2023 & 2030
5.2. Segment Dashboard
5.3. Global Neonatal Toxicology Market by Technology Outlook
5.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
5.4.1. Mass spectroscopy
5.4.1.1. Mass spectroscopy market estimates and forecasts 2018 to 2030 (USD Million)
5.4.2. Immunoassay
5.4.2.1. Immunoassay market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 6. NEONATAL TOXICOLOGY MARKET: DRUG TYPE ESTIMATES & TREND ANALYSIS
6.1. Drug type Market Share, 2023 & 2030
6.2. Segment Dashboard
6.3. Global Neonatal Toxicology Market by Drug type Outlook
6.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
6.4.1. Cannabinoids
6.4.1.1. Cannabinoids Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.2. Opioids
6.4.2.1. Opioids Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.3. Cocaine
6.4.3.1. Cocaine Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.4. Benzodiazepines
6.4.4.1. Benzodiazepines market estimates and forecasts 2018 to 2030 (USD Million)
6.4.5. Amphetamines
6.4.5.1. Amphetamines Market estimates and forecasts 2018 to 2030 (USD Million)
6.4.6. Other illicit drugs
6.4.6.1. Other illicit drugs Market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 7. NEONATAL TOXICOLOGY MARKET: END USER ESTIMATES & TREND ANALYSIS
7.1. End User Market Share, 2023 & 2030
7.2. Segment Dashboard
7.3. Global Neonatal Toxicology Market by End User Outlook
7.4. Market Size & Forecasts and Trend Analyses, 2018 to 2030 for the following
7.4.1. Hospitals
7.4.1.1. Hospitals Market estimates and forecasts 2018 to 2030 (USD Million)
7.4.2. Clinical Laboratories
7.4.2.1. Clinical Laboratories Market estimates and forecasts 2018 to 2030 (USD Million)
7.4.3. Others
7.4.3.1. Others Market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 8. NEONATAL TOXICOLOGY MARKET: REGIONAL ESTIMATES & TREND ANALYSIS
8.1. Regional Market Share Analysis, 2023 & 2030
8.2. Regional Market Dashboard
8.3. Global Regional Market Snapshot
8.4. Market Size & Forecasts Trend Analysis, 2018 to 2030:
8.5. North America
8.5.1. North America
8.5.2. U.S.
8.5.2.1. Key country dynamics
8.5.2.2. Regulatory framework
8.5.2.3. Competitive scenario
8.5.2.4. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
8.5.3. Canada
8.5.3.1. Key country dynamics
8.5.3.2. Regulatory framework
8.5.3.3. Competitive scenario
8.5.3.4. Canada market estimates and forecasts 2018 to 2030 (USD Million)
8.5.4. Mexico
8.5.4.1. Key country dynamics
8.5.4.2. Regulatory framework
8.5.4.3. Competitive scenario
8.5.4.4. Mexico market estimates and forecasts 2018 to 2030 (USD Million)
8.6. Europe
8.6.1. Europe
8.6.2. UK
8.6.2.1. Key country dynamics
8.6.2.2. Regulatory framework/ Reimbursement
8.6.2.3. Competitive scenario
8.6.2.4. UK market estimates and forecasts 2018 to 2030 (USD Million)
8.6.3. Germany
8.6.3.1. Key country dynamics
8.6.3.2. Regulatory framework/ Reimbursement
8.6.3.3. Competitive scenario
8.6.3.4. Germany market estimates and forecasts 2018 to 2030 (USD Million)
8.6.4. France
8.6.4.1. Key country dynamics
8.6.4.2. Regulatory framework/ Reimbursement
8.6.4.3. Competitive scenario
8.6.4.4. France market estimates and forecasts 2018 to 2030 (USD Million)
8.6.5. Italy
8.6.5.1. Key country dynamics
8.6.5.2. Regulatory framework/ Reimbursement
8.6.5.3. Competitive scenario
8.6.5.4. Italy market estimates and forecasts 2018 to 2030 (USD Million)
8.6.6. Spain
8.6.6.1. Key country dynamics
8.6.6.2. Regulatory framework
8.6.6.3. Competitive scenario
8.6.6.4. Spain market estimates and forecasts 2018 to 2030 (USD Million)
8.6.7. Norway
8.6.7.1. Key country dynamics
8.6.7.2. Regulatory framework
8.6.7.3. Competitive scenario
8.6.7.4. Norway market estimates and forecasts 2018 to 2030 (USD Million)
8.6.8. Sweden
8.6.8.1. Key country dynamics
8.6.8.2. Regulatory framework
8.6.8.3. Competitive scenario
8.6.8.4. Sweden market estimates and forecasts 2018 to 2030 (USD Million)
8.6.9. Denmark
8.6.9.1. Key country dynamics
8.6.9.2. Regulatory framework/ Reimbursement
8.6.9.3. Competitive scenario
8.6.9.4. Denmark market estimates and forecasts 2018 to 2030 (USD Million)
8.7. Asia Pacific
8.7.1. Asia Pacific
8.7.2. Japan
8.7.2.1. Key country dynamics
8.7.2.2. Regulatory framework/ Reimbursement
8.7.2.3. Competitive scenario
8.7.2.4. Japan market estimates and forecasts 2018 to 2030 (USD Million)
8.7.3. China
8.7.3.1. Key country dynamics
8.7.3.2. Regulatory framework/ Reimbursement
8.7.3.3. Competitive scenario
8.7.3.4. China market estimates and forecasts 2018 to 2030 (USD Million)
8.7.4. India
8.7.4.1. Key country dynamics
8.7.4.2. Regulatory framework/ Reimbursement
8.7.4.3. Competitive scenario
8.7.4.4. India market estimates and forecasts 2018 to 2030 (USD Million)
8.7.5. Australia
8.7.5.1. Key country dynamics
8.7.5.2. Regulatory framework/ Reimbursement
8.7.5.3. Competitive scenario
8.7.5.4. Australia market estimates and forecasts 2018 to 2030 (USD Million)
8.7.6. South Korea
8.7.6.1. Key country dynamics
8.7.6.2. Regulatory framework/ Reimbursement
8.7.6.3. Competitive scenario
8.7.6.4. South Korea market estimates and forecasts 2018 to 2030 (USD Million)
8.7.7. Thailand
8.7.7.1. Key country dynamics
8.7.7.2. Regulatory framework/ Reimbursement
8.7.7.3. Competitive scenario
8.7.7.4. Thailand market estimates and forecasts 2018 to 2030 (USD Million)
8.8. Latin America
8.8.1. Latin America
8.8.2. Brazil
8.8.2.1. Key country dynamics
8.8.2.2. Regulatory framework
8.8.2.3. Competitive scenario
8.8.2.4. Brazil market estimates and forecasts 2018 to 2030 (USD Million)
8.8.3. Argentina
8.8.3.1. Key country dynamics
8.8.3.2. Regulatory framework/ Reimbursement
8.8.3.3. Competitive scenario
8.8.3.4. Argentina market estimates and forecasts 2018 to 2030 (USD Million)
8.9. MEA
8.9.1. MEA
8.9.2. South Africa
8.9.2.1. Key country dynamics
8.9.2.2. Regulatory framework/ Reimbursement
8.9.2.3. Competitive scenario
8.9.2.4. South Africa market estimates and forecasts 2018 to 2030 (USD Million)
8.9.3. Saudi Arabia
8.9.3.1. Key country dynamics
8.9.3.2. Regulatory framework/ Reimbursement
8.9.3.3. Competitive scenario
8.9.3.4. Saudi Arabia market estimates and forecasts 2018 to 2030 (USD Million)
8.9.4. UAE
8.9.4.1. Key country dynamics
8.9.4.2. Regulatory framework/ Reimbursement
8.9.4.3. Competitive scenario
8.9.4.4. UAE market estimates and forecasts 2018 to 2030 (USD Million)
8.9.5. Kuwait
8.9.5.1. Key country dynamics
8.9.5.2. Regulatory framework
8.9.5.3. Competitive scenario
8.9.5.4. Kuwait market estimates and forecasts 2018 to 2030 (USD Million)
CHAPTER 9. COMPETITIVE LANDSCAPE
9.1. Recent Developments & Impact Analysis, By Key Market Participants
9.2. Company/Competition Categorization
9.3. Vendor Landscape
9.3.1. List of key distributors and channel partners
9.3.2. Key customers
9.3.3. Key company market share analysis, 2023
9.3.4. Quest Diagnostics Incorporated
9.3.4.1. Company overview
9.3.4.2. Financial performance
9.3.4.3. Others benchmarking
9.3.4.4. Strategic initiatives
9.3.5. USDTL
9.3.5.1. Company overview
9.3.5.2. Financial performance
9.3.5.3. Others benchmarking
9.3.5.4. Strategic initiatives
9.3.6. Quidel Corporation
9.3.6.1. Company overview
9.3.6.2. Financial performance
9.3.6.3. Others benchmarking
9.3.6.4. Strategic initiatives
9.3.7. Thermo Fisher Scientific, Inc.
9.3.7.1. Company overview
9.3.7.2. Financial performance
9.3.7.3. Others benchmarking
9.3.7.4. Strategic initiatives
9.3.8. Omega Laboratories, Inc.
9.3.8.1. Company overview
9.3.8.2. Financial performance
9.3.8.3. Others benchmarking
9.3.8.4. Strategic initiatives
9.3.9. Bio-Rad Laboratories, Inc.
9.3.9.1. Company overview
9.3.9.2. Financial performance
9.3.9.3. Others benchmarking
9.3.9.4. Strategic initiatives
9.3.10. Agilent Technologies, Inc.
9.3.10.1. Company overview
9.3.10.2. Financial performance
9.3.10.3. Others benchmarking
9.3.10.4. Strategic initiatives
9.3.11. Laboratory Corporation of America Holdings
9.3.11.1. Company overview
9.3.11.2. Financial performance
9.3.11.3. Others benchmarking
9.3.11.4. Strategic initiatives
9.3.12. Clinical Reference Laboratory, Inc.
9.3.12.1. Company overview
9.3.12.2. Financial performance
9.3.12.3. Others benchmarking
9.3.12.4. Strategic initiatives
9.3.13. Cordant Health Solutions
9.3.13.1. Company overview
9.3.13.2. Financial performance
9.3.13.3. Others benchmarking
9.3.13.4. Strategic initiatives
LIST OF TABLES
Table 1 List of abbreviations
Table 2 North America neonatal toxicology market, by region, 2018 - 2030 (USD Million)
Table 3 North America neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
Table 4 North America neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
Table 5 North America neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
Table 6 North America neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
Table 7 U.S. neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
Table 8 U.S. neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
Table 9 U.S. neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
Table 10 U.S. neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
Table 11 Canada neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
Table 12 Canada neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
Table 13 Canada neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
Table 14 Canada neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
Table 15 Mexico neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
Table 16 Mexico neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
Table 17 Mexico neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
Table 18 Mexico neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
Table 19 Europe neonatal toxicology market, by region, 2018 - 2030 (USD Million)
Table 20 Europe neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
Table 21 Europe neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
Table 22 Europe neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
Table 23 Europe neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
Table 24 Germany neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
Table 25 Germany neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
Table 26 Germany neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
Table 27 Germany neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
Table 28 UK neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
Table 29 UK neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
Table 30 UK neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
Table 31 UK neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
Table 32 France neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
Table 33 France neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
Table 34 France neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
Table 35 France neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
Table 36 Italy neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
Table 37 Italy neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
Table 38 Italy neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
Table 39 Italy neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
Table 40 Spain neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
Table 41 Spain neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
Table 42 Spain neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
Table 43 Spain neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
Table 44 Denmark neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
Table 45 Denmark neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
Table 46 Denmark neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
Table 47 Denmark neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
Table 48 Sweden neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
Table 49 Sweden neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
Table 50 Sweden neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
Table 51 Sweden neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
Table 52 Norway neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
Table 53 Norway neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
Table 54 Norway neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
Table 55 Norway neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
Table 56 Asia Pacific neonatal toxicology market, by region, 2018 - 2030 (USD Million)
Table 57 Asia Pacific neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
Table 58 Asia Pacific neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
Table 59 Asia Pacific neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
Table 60 Asia Pacific neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
Table 61 China neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
Table 62 China neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
Table 63 China neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
Table 64 China neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
Table 65 Japan neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
Table 66 Japan neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
Table 67 Japan neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
Table 68 Japan neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
Table 69 India neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
Table 70 India neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
Table 71 India neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
Table 72 India neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
Table 73 South Korea neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
Table 74 South Korea neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
Table 75 South Korea neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
Table 76 South Korea neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
Table 77 Australia neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
Table 78 Australia neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
Table 79 Australia neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
Table 80 Australia neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
Table 81 Thailand neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
Table 82 Thailand neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
Table 83 Thailand neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
Table 84 Thailand neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
Table 85 Latin America neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
Table 86 Latin America neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
Table 87 Latin America neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
Table 88 Latin America neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
Table 89 Brazil neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
Table 90 Brazil neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
Table 91 Brazil neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
Table 92 Brazil neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
Table 93 Argentina neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
Table 94 Argentina neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
Table 95 Argentina neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
Table 96 Argentina neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
Table 97 MEA neonatal toxicology market, by region, 2018 - 2030 (USD Million)
Table 98 MEA neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
Table 99 MEA neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
Table 100 MEA neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
Table 101 MEA neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
Table 102 South Africa neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
Table 103 South Africa neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
Table 104 South Africa neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
Table 105 South Africa neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
Table 106 Saudi Arabia neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
Table 107 Saudi Arabia neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
Table 108 Saudi Arabia neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
Table 109 Saudi Arabia neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
Table 110 UAE neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
Table 111 UAE neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
Table 112 UAE neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
Table 113 UAE neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
Table 114 Kuwait neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
Table 115 Kuwait neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
Table 116 Kuwait neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
Table 117 Kuwait neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
Table 1 List of abbreviations
Table 2 North America neonatal toxicology market, by region, 2018 - 2030 (USD Million)
Table 3 North America neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
Table 4 North America neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
Table 5 North America neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
Table 6 North America neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
Table 7 U.S. neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
Table 8 U.S. neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
Table 9 U.S. neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
Table 10 U.S. neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
Table 11 Canada neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
Table 12 Canada neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
Table 13 Canada neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
Table 14 Canada neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
Table 15 Mexico neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
Table 16 Mexico neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
Table 17 Mexico neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
Table 18 Mexico neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
Table 19 Europe neonatal toxicology market, by region, 2018 - 2030 (USD Million)
Table 20 Europe neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
Table 21 Europe neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
Table 22 Europe neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
Table 23 Europe neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
Table 24 Germany neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
Table 25 Germany neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
Table 26 Germany neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
Table 27 Germany neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
Table 28 UK neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
Table 29 UK neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
Table 30 UK neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
Table 31 UK neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
Table 32 France neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
Table 33 France neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
Table 34 France neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
Table 35 France neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
Table 36 Italy neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
Table 37 Italy neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
Table 38 Italy neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
Table 39 Italy neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
Table 40 Spain neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
Table 41 Spain neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
Table 42 Spain neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
Table 43 Spain neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
Table 44 Denmark neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
Table 45 Denmark neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
Table 46 Denmark neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
Table 47 Denmark neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
Table 48 Sweden neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
Table 49 Sweden neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
Table 50 Sweden neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
Table 51 Sweden neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
Table 52 Norway neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
Table 53 Norway neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
Table 54 Norway neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
Table 55 Norway neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
Table 56 Asia Pacific neonatal toxicology market, by region, 2018 - 2030 (USD Million)
Table 57 Asia Pacific neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
Table 58 Asia Pacific neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
Table 59 Asia Pacific neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
Table 60 Asia Pacific neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
Table 61 China neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
Table 62 China neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
Table 63 China neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
Table 64 China neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
Table 65 Japan neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
Table 66 Japan neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
Table 67 Japan neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
Table 68 Japan neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
Table 69 India neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
Table 70 India neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
Table 71 India neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
Table 72 India neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
Table 73 South Korea neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
Table 74 South Korea neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
Table 75 South Korea neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
Table 76 South Korea neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
Table 77 Australia neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
Table 78 Australia neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
Table 79 Australia neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
Table 80 Australia neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
Table 81 Thailand neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
Table 82 Thailand neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
Table 83 Thailand neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
Table 84 Thailand neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
Table 85 Latin America neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
Table 86 Latin America neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
Table 87 Latin America neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
Table 88 Latin America neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
Table 89 Brazil neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
Table 90 Brazil neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
Table 91 Brazil neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
Table 92 Brazil neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
Table 93 Argentina neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
Table 94 Argentina neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
Table 95 Argentina neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
Table 96 Argentina neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
Table 97 MEA neonatal toxicology market, by region, 2018 - 2030 (USD Million)
Table 98 MEA neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
Table 99 MEA neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
Table 100 MEA neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
Table 101 MEA neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
Table 102 South Africa neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
Table 103 South Africa neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
Table 104 South Africa neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
Table 105 South Africa neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
Table 106 Saudi Arabia neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
Table 107 Saudi Arabia neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
Table 108 Saudi Arabia neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
Table 109 Saudi Arabia neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
Table 110 UAE neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
Table 111 UAE neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
Table 112 UAE neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
Table 113 UAE neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
Table 114 Kuwait neonatal toxicology market, by specimen, 2018 - 2030 (USD Million)
Table 115 Kuwait neonatal toxicology market, by technology, 2018 - 2030 (USD Million)
Table 116 Kuwait neonatal toxicology market, by drug, 2018 - 2030 (USD Million)
Table 117 Kuwait neonatal toxicology market, by end use, 2018 - 2030 (USD Million)
LIST OF FIGURES
Fig. 1 Information Procurement
Fig. 2 Primary Research Pattern
Fig. 3 Market Research Approaches
Fig. 4 Value Chain-Based Sizing & Forecasting
Fig. 5 Market Formulation & Validation
Fig. 6 U.S. Female External Catheter Market, Market Segmentation
Fig. 7 Market Driver Analysis (Current & Future Impact)
Fig. 8 Market Restraint Analysis (Current & Future Impact)
Fig. 9 Market Opportunity Analysis (Current & Future Impact)
Fig. 10 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
Fig. 11 Porter’s Five Forces Analysis
Fig. 12 Regional Marketplace: Key Takeaways
Fig. 13 U.S. Female External Catheter Market, for Silicone, 2018 - 2030 (USD Million)
Fig. 14 U.S. Female External Catheter Market, for Latex, 2018 - 2030 (USD Million)
Fig. 15 U.S. Female External Catheter Market, for Diabetes, 2018 - 2030 (USD Million)
Fig. 16 U.S. Female External Catheter Market, for Strokes, 2018 - 2030 (USD Million)
Fig. 17 U.S. Female External Catheter Market, for Alzheimer's disease, 2018 - 2030 (USD Million)
Fig. 18 U.S. Female External Catheter Market, for Parkinson's disease, 2018 - 2030 (USD Million)
Fig. 19 U.S. Female External Catheter Market, for Spinal Cord Injury, 2018 - 2030 (USD Million)
Fig. 20 U.S. Female External Catheter Market, for Bladder Cancer, 2018 - 2030 (USD Million)
Fig. 21 U.S. Female External Catheter Market, for Ovarian Cancer, 2018 - 2030 (USD Million)
Fig. 22 U.S. Female External Catheter Market, for Multiple Sclerosis, 2018 - 2030 (USD Million)
Fig. 23 U.S. Female External Catheter Market, for Others, 2018 - 2030 (USD Million)
Fig. 24 U.S. Female External Catheter Market, for Stress Urinary Incontinence, 2018 - 2030 (USD Million)
Fig. 25 U.S. Female External Catheter Market, for Urge/OAB (Overactive Bladder), 2018 - 2030 (USD Million)
Fig. 26 U.S. Female External Catheter Market, for Overflow, 2018 - 2030 (USD Million)
Fig. 27 U.S. Female External Catheter Market, for Functional, 2018 - 2030 (USD Million)
Fig. 28 Regional Outlook, 2023 & 2030
Fig. 29 U.S. Female External Catheter Market, for Mixed, 2018 - 2030 (USD Million)
Fig. 30 Regional Outlook, 2023 & 2030
Fig. 31 U.S. Female External Catheter Market, for Reflex, 2018 - 2030 (USD Million)
Fig. 32 Regional Outlook, 2023 & 2030
Fig. 33 U.S. Female External Catheter Market, for Severe Incontinence, 2018 - 2030 (USD Million)
Fig. 34 Regional Outlook, 2023 & 2030
Fig. 35 South U.S. Female External Catheter Market, 2018 - 2030 (USD Million)
Fig. 36 West U.S. Female External Catheter Market, 2018 - 2030 (USD Million)
Fig. 37 Midwest U.S. Female External Catheter Market, 2018 - 2030 (USD Million)
Fig. 38 Northeast U.S. Female External Catheter Market, 2018 - 2030 (USD Million)
Fig. 1 Information Procurement
Fig. 2 Primary Research Pattern
Fig. 3 Market Research Approaches
Fig. 4 Value Chain-Based Sizing & Forecasting
Fig. 5 Market Formulation & Validation
Fig. 6 U.S. Female External Catheter Market, Market Segmentation
Fig. 7 Market Driver Analysis (Current & Future Impact)
Fig. 8 Market Restraint Analysis (Current & Future Impact)
Fig. 9 Market Opportunity Analysis (Current & Future Impact)
Fig. 10 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
Fig. 11 Porter’s Five Forces Analysis
Fig. 12 Regional Marketplace: Key Takeaways
Fig. 13 U.S. Female External Catheter Market, for Silicone, 2018 - 2030 (USD Million)
Fig. 14 U.S. Female External Catheter Market, for Latex, 2018 - 2030 (USD Million)
Fig. 15 U.S. Female External Catheter Market, for Diabetes, 2018 - 2030 (USD Million)
Fig. 16 U.S. Female External Catheter Market, for Strokes, 2018 - 2030 (USD Million)
Fig. 17 U.S. Female External Catheter Market, for Alzheimer's disease, 2018 - 2030 (USD Million)
Fig. 18 U.S. Female External Catheter Market, for Parkinson's disease, 2018 - 2030 (USD Million)
Fig. 19 U.S. Female External Catheter Market, for Spinal Cord Injury, 2018 - 2030 (USD Million)
Fig. 20 U.S. Female External Catheter Market, for Bladder Cancer, 2018 - 2030 (USD Million)
Fig. 21 U.S. Female External Catheter Market, for Ovarian Cancer, 2018 - 2030 (USD Million)
Fig. 22 U.S. Female External Catheter Market, for Multiple Sclerosis, 2018 - 2030 (USD Million)
Fig. 23 U.S. Female External Catheter Market, for Others, 2018 - 2030 (USD Million)
Fig. 24 U.S. Female External Catheter Market, for Stress Urinary Incontinence, 2018 - 2030 (USD Million)
Fig. 25 U.S. Female External Catheter Market, for Urge/OAB (Overactive Bladder), 2018 - 2030 (USD Million)
Fig. 26 U.S. Female External Catheter Market, for Overflow, 2018 - 2030 (USD Million)
Fig. 27 U.S. Female External Catheter Market, for Functional, 2018 - 2030 (USD Million)
Fig. 28 Regional Outlook, 2023 & 2030
Fig. 29 U.S. Female External Catheter Market, for Mixed, 2018 - 2030 (USD Million)
Fig. 30 Regional Outlook, 2023 & 2030
Fig. 31 U.S. Female External Catheter Market, for Reflex, 2018 - 2030 (USD Million)
Fig. 32 Regional Outlook, 2023 & 2030
Fig. 33 U.S. Female External Catheter Market, for Severe Incontinence, 2018 - 2030 (USD Million)
Fig. 34 Regional Outlook, 2023 & 2030
Fig. 35 South U.S. Female External Catheter Market, 2018 - 2030 (USD Million)
Fig. 36 West U.S. Female External Catheter Market, 2018 - 2030 (USD Million)
Fig. 37 Midwest U.S. Female External Catheter Market, 2018 - 2030 (USD Million)
Fig. 38 Northeast U.S. Female External Catheter Market, 2018 - 2030 (USD Million)
